RT Journal Article
SR Electronic
T1 Prognostic factors for severity and mortality in patients infected with COVID-19: A living systematic review protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.08.20056598
DO 10.1101/2020.04.08.20056598
A1 Izcovich, Ariel
A1 Ragusa, Martín
A1 Sanguine, Verónica
A1 Tortosa, Fernando
A1 Espinosa, Federico
A1 Agnoletti, Camila
A1 Lavena Marzio, María Andrea
A1 Ceirano, Agustina
A1 Bengolea, Agustín
A1 Saavedra, Ezequiel
A1 Catalano, Hugo N.
A1 Rada, Gabriel
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/04/11/2020.04.08.20056598.abstract
AB Objective The objective of our systematic review is to identify prognostic factors that can potentially be used in decision-making related to the care of patients infected with COVID-19.Design This is the protocol of a living systematic review.Data sources We will conduct searches in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature and in a centralised repository in L·OVE (Living OVerview of Evidence). L·OVE is a platform that maps PICO questions to evidence from Epistemonikos database. In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence covered and customised to group all COVID-19 evidence in one place. The search will continue until the day before submission to a journal.Eligibility criteria for selecting studies and methods We will follow a common protocol for multiple parallel systematic reviews, already published and submitted to PROSPERO (awaiting ID allocation).We will include studies that assess patients with confirmed or suspected SARS-CoV-2 infection and inform the relation between potential prognostic factors and death or disease severity. Two groups of two reviewers will independently screen studies for eligibility, extract data and assess the risk of bias. We will perform meta-analyses and use GRADE to assess the certainty of evidence for each prognostic factor and outcome.A living, web-based version of this review will be openly available during the COVID-19 pandemic. We will resubmit it if the conclusions change or there are substantial updates.Ethics and dissemination No ethics approval is considered necessary. The results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media.PROSPERO Registration Submitted to PROSPERO (awaiting ID allocation).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was not commissioned by any organisation and did not receive external funding. Epistemonikos Foundation is providing training, support and tools at no cost for all the members of the COVID-19 L·OVE Working Group.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that will support the findings of this study will be openly available.